Skip to main content

Advertisement

SpringerLink
Log in

Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide

  • Research Article
  • Published:
Tumor Biology

Abstract

The study aims to investigate the changes and regulation of androgen receptor and insulin-like growth factor-1 in the PC3 prostate cells treated with 5α-dihydrotestosterone, estrone, and flutamide. The PC3 cells were cultured and treated with 5α-dihydrotestosterone, estrone, and flutamide. Immunocytochemistry and Western blot were used to detect the expression of androgen receptor and insulin-like growth factor-1. The androgen receptor expression was analyzed by Western blot and optic density scan in the presence or absence of various kinase inhibitors. The statistical calculations were performed with the statistics-analyzing software package SPSS 13.0. A P <0.05 was considered statistically significant. The concentrations of 5α-dihydrotestosterone and flutamide could almost not change the expression of androgen receptor and insulin-like growth factor-1 in PC3. But, the concentrations of estrone could increase the expression of androgen receptor and insulin-like growth factor-1 when PC3 cells are exposed to the studied concentration at various times. The expression of androgen receptor was regulated by the inhibitor of signal pathways of PI3, MEK1/2, and JUK. The expressions of androgen receptor and insulin-like growth factor-1 were influenced by estrone and were not influenced by 5α-dihydrotestosterone and flutamide in PC3 cells. And, the expression of androgen receptor was regulated by multiple signal pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Naiki T, Okamura T, Kawai N, Sakagami H, Yamada Y, Fujita K, et al. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. Asian Pac J Cancer Prev. 2009;10:71–4.

    PubMed  Google Scholar 

  2. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011;18:R175–82.

    Article  PubMed  CAS  Google Scholar 

  3. Shiota M, Yokomizo A, Fujimoto N, Naito S. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Curr Cancer Drug Targets. 2011;11:870–81.

    Article  PubMed  CAS  Google Scholar 

  4. Otsuka T, Iguchi K, Fukami K, Ishii K, Usui S, Sugimura Y, et al. Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells. Tumor Biol. 2011;32:1097–102.

    Article  CAS  Google Scholar 

  5. Tong DY, Wen XQ, Jin Y, Liu ZW, Sun HY, Zhou FJ, et al. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide. Asian Pac J Cancer Prev. 2010;11:1805–9.

    Google Scholar 

  6. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 2005;23:1–9.

    Article  PubMed  CAS  Google Scholar 

  7. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort. Prostate. 2010;70:906–15.

    PubMed  CAS  Google Scholar 

  8. Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y, et al. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a nested case–control study in large scale cohort study in Japan. Asian Pac J Cancer Prev. 2009;10:57–61.

    PubMed  Google Scholar 

  9. Wang Y, Shao C, Shi CH, Zhang L, Yue HH, Wang PF, et al. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. Asian J Androl. 2005;7:375–80.

    Article  PubMed  CAS  Google Scholar 

  10. Lv T, Tian B, Zhang X. Changes of androgen receptor expression in hormonal dependent prostatic cancer and independent prostatic cancer. Medical Journal of Wuhan University. 2007;28:181–4.

    Google Scholar 

  11. Fuse H, Korenaga S, Sakari M, Hiyama T, Ito T, Kimura K, et al. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression. Prostate. 2007;67:630–7.

    Article  PubMed  CAS  Google Scholar 

  12. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, et al. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol. 2010;17:337–45.

    Article  PubMed  CAS  Google Scholar 

  13. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol. 2009;27:36–41.

    Article  PubMed  CAS  Google Scholar 

  14. Yanase T, Fan W. Modification of androgen receptor function by IGF-1 signaling implications in the mechanism of refractory prostate carcinoma. Vitam Horm. 2009;80:649–66.

    Article  PubMed  CAS  Google Scholar 

  15. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001;61:6276–80.

    PubMed  CAS  Google Scholar 

  16. Takahara K, Azuma H, Sakamoto T, Kiyama S, Inamoto T, Ibuki N, et al. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression. Anticancer Res. 2009;29:2497–505.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank Prof. Guo quan Gao in the Department of Biochemistry and Molecular Biology, Zhong shan School of Medicine, Sun Yat-Sen University, for technical direction. This study was supported by the Special Fund for Basic Research from the Ministry of Education, P.R. China (project no. 505015).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Forensic Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Zhongshan II road 74#, Guangzhou, 510080, China

    Da yue Tong, Xin yao Wu & Hong yu Sun

  2. The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510275, China

    Yi Jin

  3. Sun Yat-sen University Cancer Centers, Guangzhou, 510080, China

    Zhuo wei Liu & Fang jian Zhou

Authors
  1. Da yue Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin yao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong yu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhuo wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fang jian Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Da yue Tong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tong, D.y., Wu, X.y., Sun, H.y. et al. Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide. Tumor Biol. 33, 2151–2158 (2012). https://doi.org/10.1007/s13277-012-0475-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0475-3

Keywords

Search

Navigation